Lipoteichoic acid

CAS No. 56411-57-5

Lipoteichoic acid( —— )

Catalog No. M35221 CAS No. 56411-57-5

Lipoteichoic acid, a polymer of Staphylococcus aureus cell wall, activates the complement system by inducing C3 and inhibiting CD55, and reduces fat deposition via the IGF-1 pathway.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 298 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Lipoteichoic acid
  • Note
    Research use only, not for human use.
  • Brief Description
    Lipoteichoic acid, a polymer of Staphylococcus aureus cell wall, activates the complement system by inducing C3 and inhibiting CD55, and reduces fat deposition via the IGF-1 pathway.
  • Description
    Lipoteichoic acid, a cell wall component of Staphylococcus aureus, activates the complement system via C3 induction and CD55 inhibition.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    Complement System
  • Recptor
    Complement System
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    56411-57-5
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (Ultrasonic ) H2O : 10 mg/mL (Ultrasonic)
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Bong Jun Jung, et al. Lipoteichoic Acid from Staphylococcus aureus Activates the Complement System via C3 Induction and CD55 Inhibition. Microorganisms. 2021 May 24;9(6):1135.?
molnova catalog
related products
  • W-54011

    A potent and orally active non-peptide C5a receptor (CD88;C5aR) antagonist with Ki of 2.2 nM.

  • C3a 70-77 2TFA(63555...

    C3a 70-77 2TFA is an octapeptide corresponding to the COOH terminus of C3a.

  • Ravulizumab

    Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation.